OBJECTIVES The purpose of this study was to determine the phenotypic presentation, causes, and outcome of fetal cardiomyopathy (CM) and to identify early predictors of outcome. BACKGROUND Although prenatal diagnosis is possible, there is a paucity of information about fetal CM.
The hypertrophic phenotype was predominantly (76%) related to maternal diabetes and twin-twin transfusion syndrome. Cardiac pathology secondary to these conditions is often reversible (9, 10) , with a substantially better long-term prognosis compared with primary CM. Accordingly, the purpose of this single-center cohort study was to assess the disease pattern and outcome of disorders in which the primary pathology is the fetal myocardium and to determine epidemiological and hemodynamic markers associated with adverse outcomes.
METHODS

The Research Ethics Board of the Hospital for Sick
Children approved this retrospective study. and the mean of 3 consecutive measurements were compared with institutional reference data (11) .
Findings considered abnormal included ventricular shortening fraction <28%, left ventricular (LV) isovolumic relaxation time >43 ms, LV myocardial performance index (MPI) >0.48, ventricular enddiastolic dimensions >2 z-scores, cardiothoracic area ratio (CTR) >35%, and more than mild valvar regurgitation (11) (12) (13) (14) . For fetuses with normal sinus rhythm, the severity of heart failure was quantified using the cardiovascular profile score (CVPS) ( Table 1 ) with 2 modifications to the original scoring system (replacement of "skin edema" with "fetal hydrops" and elimination of "tricuspid valve dP/dt," which had not been routinely measured, as 2-point criteria) (12) .
Interrater agreement was assessed on 10 randomly selected fetal studies for the following variables:
CVPS, CTR, systolic and diastolic ventricular diameters, ventricular septal wall thickness, isovolumic relaxation time, and MPI. Interrater bias was nonstatistically significant for all parameters. Interrater correlation was statistically significant (r > 0.8, p < 0.01) for all parameters with the exception of LV MPI (r ¼ 0.55, p > 0.05). These data confirm that interrater reproducibility was excellent for most parameters.
DEFINITIONS. CM was divided into 2 anatomic phenotypes, depending on the presence or absence of myocardial hypertrophy at final assessment. This approach was selected to allow for phenotypic crossover that can occur during fetal life. Hypertrophic cardiomyopathy (HCM) demonstrated inappropriate ventricular hypertrophy and was defined by diastolic ventricular wall thickness >2 z-scores at the last echocardiogram or at autopsy (15, 16) . Nonhypertrophic cardiomyopathy (NHCM) was defined by cardiac dysfunction in the absence of myocardial hypertrophy at any stage and included dilated and nondilated phenotypes (17, 18) . Dilated NHCM was defined by ventricular enlargement >2 z-scores of 1 or both ventricles. LV noncompaction was diagnosed on the basis of prominent trabeculations and multiple deep recesses at the ventricular apex (19, 20) . Fibrosis and calcification were identified as areas of persistently echogenic endomyocardium (8, 16, 21) . 
RESULTS
Over a period of 12 years, we diagnosed 61 fetuses with CM as the primary abnormality, suggesting an incidence of 6.2 (95% CI: 3.8 to 8.5) per 100,000. Table 2 . syndrome, congenital glycosylation disorder, and familial HCM, all of whom initially presented with marked isolated diastolic dysfunction followed by development of myocardial hypertrophy before (n ¼ 2) or early after (n ¼ 2) birth.
Etiologies, spectrum of abnormalities, and outcome of NHCM and HCM are shown in Tables 4 and 5 
or third-(n ¼ 5) degree heart block, and LV noncompaction (n ¼ 8). Etiologies were highly variable and included rare genetic-metabolic, familial, and inflammatory disorders ( Table 4) . Values are the number of cases, mean AE SD, or n (%) of cases with an abnormal finding. *Cases with normal cardiac rhythm.
CI ¼ confidence interval; CVPS ¼ modified cardiovascular profile score; HR ¼ hazard ratio; PV ¼ pulmonary vein; other abbreviations as in Tables 1 and 2 .
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Fetal Cardiomyopathies
A U G U S T 2 0 1 4 : 4 0 3 -1 1 child is clinically well without signs of ventricular involvement.
The ventricular myocardium was predominantly affected in 38 fetuses (95%). In 18, the pregnancy was terminated (n ¼ 9; 23%) or ended with fetal demise HYPERTROPHIC CM. In all 21 cases, myocardial hypertrophy eventually affected both ventricles.
The main associations were with homozygous alpha-thalassemia (n ¼ 5) and Noonan syndrome (n ¼ 2). Other conditions were observed in isolation (Table 5) . Four pregnancies (19%) were terminated, whereas 8 fetuses (38%) died in utero. Repeated fetal 
*Phenotypes at last fetal, postmortem, or postnatal examination are shown.
CDG ¼ congenital disorder of glycosylation; HOCM ¼ hypertrophic obstructive cardiomyopathy; other abbreviations as in Table 4 . 
Giant right atrium AVB I (n ¼ 1)
Atrial flutter *Phenotypes at last fetal, post-mortem, or post-natal examination are shown.
AVB ¼ atrio-ventricular block; CAVB ¼ complete atrio-ventricular block; CNS ¼ central nervous system; Dupl ¼ duplication anomaly; EFE ¼ endocardial fibroelastosis; HTX ¼ heart transplantation; IUD ¼ intrauterine demise; MC ¼ mitochondrial complex; MYH7 mutation ¼ myosin storage myopathy; NC ¼ ventricular noncompaction; NND ¼ neonatal demise; TOP ¼ termination of pregnancy; other abbreviations as in Table 2 . 95% CI: 1.9 to 27.9; p ¼ 0.004), respectively. Table 3 compares characteristics among survivors and nonsurvivors from fetal diagnosis to infancy. The incidence of prenatally diagnosed CM (6.2 of 100,000) in our population is comparable to that reported in children younger than 1 year of age in Finland (4.1 of 100,000), Australia (7.8 of 100,000), and the United States (8.34 of 100,000) and higher than among older children and adults (2) (3) (4) . Similar to the post-natal experience (6), we found that prenatally In contrast to NHCM, we found that fetal HCM was associated with a dismal rate (12%) of transplantation-free survival from diagnosis to school age, making this an even worse condition in terms of survival than any other form of severe congenital heart disease (29) . Importantly, none of the survivors beyond the first year of life had myocardial wall thickness z-scores >2.5 at the baseline examination, suggesting that restrictive Ventricular noncompaction has been recognized as a pre-natally detectable entity, especially in the past decade, typically in association with structural heart disease, fetal hydrops, and demise (19, 26, 33, 34) . In 
